KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Receivables - Net (2020 - 2022)

Historic Receivables - Net for Vir Biotechnology (VIR) over the last 3 years, with Q2 2022 value amounting to $7.0 million.

  • Vir Biotechnology's Receivables - Net changed N/A to $7.0 million in Q2 2022 from the same period last year, while for Jun 2022 it was $7.0 million, marking a year-over-year change of. This contributed to the annual value of $773.1 million for FY2021, which is N/A changed from last year.
  • According to the latest figures from Q2 2022, Vir Biotechnology's Receivables - Net is $7.0 million.
  • Vir Biotechnology's Receivables - Net's 5-year high stood at $1.2 billion during Q1 2022, with a 5-year trough of $3.8 million in Q2 2020.
  • In the last 3 years, Vir Biotechnology's Receivables - Net had a median value of $102.8 million in 2021 and averaged $368.8 million.
  • The largest annual percentage gain for Vir Biotechnology's Receivables - Net in the last 5 years was 98725.42% (2022), contrasted with its biggest fall of 98725.42% (2022).
  • Over the past 3 years, Vir Biotechnology's Receivables - Net (Quarter) stood at $3.8 million in 2020, then surged by 20244.18% to $773.1 million in 2021, then crashed by 99.09% to $7.0 million in 2022.
  • Its Receivables - Net stands at $7.0 million for Q2 2022, versus $1.2 billion for Q1 2022 and $773.1 million for Q4 2021.